Biapenem CAS No: 120410-24-4 Doripenem CAS No: 148016-81-3 Ertapenem CAS No: 153832-46-3 Imipenem CAS No: 74431-23-5 Meropenem CAS No: 96036-03-2 Panipenem CAS No: 87726-17-8 A new publication is out called “May 19, 2016 – Tackling Drug-Resistant Infections Globally: final report and recommendations” and it highlights the antibiotic-resistant infections which are being seen for the 1st[…]
Carbapenems API’s for Antibiotic Resistance
Antibiotic, Drug Research & Development API Tags: antibioticCDCUnited States May 27, 2016
Exenatide Capsule Gleans Patent in Israel
Anti-Diabetic, Blood Glucose Regulator, Drug Research & Development API, OTC and Compounding Product, Synthetic Peptide Tags: United States Jun 17, 2015
Known as the brand name Byetta in the United States, which is marketed by AstraZeneca, Exenatide is a GLP-1 analog that is currently offered as an injectable treatment for type 2 diabetes. In mid-January 2015 Oramed Pharmaceuticals was granted a patent in Israel for the oral administration of Exenatide. As an effectual therapy for patients[…]
Micafungin Remains a Viable Treatment for Candida Infections
Anti-Fungal, Drug Research & Development API, FDA Approved 2013 Tags: United States Apr 08, 2015
As the fourth most common cause of hospital-acquired bloodstream infections in the United States, Invasive Candidiasis is a concern for any patient battling a fungal infection. Micafungin, also known as the brand name Mycamine, which is marketed by Astellas, is an effective antifungal agent. By inhibiting the synthesis of 1,3-beta-D-glucan, Micafungin proves to be a[…]
Data from Loteprednol Study to be Presented to Ophthalmic Congress in the Second Half of 2015
Drug Research & Development API Tags: United States Mar 31, 2015
With primary endpoints of a phase 3 trial of Loteprednol Etabonate being met in the fall of 2014, researchers are anxiously awaiting additional data to present in late 2015. The success of Loteprednol for treating both inflammation and pain in post-cataract surgical patients has led trial leaders to anticipate continued positive results to present to[…]
Alemtuzumab is a Formidable Therapy for Cancer and Multiple Sclerosis
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: MSmultiple sclerosisUnited States Mar 18, 2015
Known as the brand name Campath, which is marketed by Genzyme, Alemtuzumab is a proven therapy for leukemias, lymphomas and recently, multiple sclerosis. As a monoclonal antibody Alemtuzumab effectively binds to the CD52 protein which occurs on cancerous B and T cell lymphocytes. After attaching to the protein on the cells Alemtuzumab elicits other immune[…]
Tadalafil Tested as Possible Dementia Therapy
Blood Product, Cardiovascular Agent, Drug Research & Development API, OTC and Compounding Product Tags: erectile dysfunctionUnited States Mar 16, 2015
The close of 2014 brought exciting news for patients suffering from dementia with the announcement that Tadalafil, a commonly used drug that treats erectile dysfunction, is being tested as a treatment for dementia. The Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Society UK shared the news of their partnership and funding, which would be earmarked[…]
Rizatriptan Gets FDA Nod as New Generic for Migraine Therapy
Anti-Inflammatory, Anti-Migraine, FDA Approved 2015 Tags: migraine headachesmigrainesserotoninUnited States Mar 12, 2015
On January 5, 2015 Jubilant Life Sciences received an FDA nod for their Rizatriptan generic formulation, paving the way for more generic forms of Merck’s blockbuster migraine medication Maxalt. The strengths approved for generic production are both 5 milligrams and 10 milligrams, which makes up an estimated 70 million dollar market. Rizatriptan is an efficacious[…]
Can Dapagliflozin and Canagliflozin Fight Type 2 Diabetes and Obesity?
Anti-Diabetic, Drug Research & Development API Tags: DapagliflozinEuropeObesityUnited States Mar 03, 2015
An article published in January 2015 in Diabetes, Obesity and Metabolism explored the pharmacodynamics and the benefits of Dapagliflozin and Canagliflozin in the fight against obesity and type 2 diabetes. This double-blind, randomized study involved both males and females between the ages of 18 and 55. All participants were deemed healthy and free of significant[…]
Liraglutide FDA Approval Brings First Ever Injectable Weight Loss Drug
Anti-Diabetic, Anti-Obesity Product, FDA Approved 2014 Tags: LiraglutideUnited States Jan 26, 2015
The close of 2014 brought exciting news for Novo Nordisk’s innovative weight loss drug Saxenda. The Liraglutide FDA approval is the first of its kind as it’s the only available injectable treatment for obesity. The FDA overwhelmingly gave a nod to this easy to use form of Liraglutide as a safe and effectual option for[…]
